Abstract:To investigate the efficacy and the roles of immune interruptions on blocking mother-to-infant transmission of hepatitis B virus (HBV),667 pregnant women who were seropositive for hepatitis B surface antigen (HBsAg) were enrolled. According to the lab test results of HBV e antigen (HBeAg) and HBV DNA in the mothers, the mothers were divided into either HBeAg-positive group or HBeAg-negative group, and either HBV DNA-positive group or HBV DNA-negative group. Depending on whether the mothers were receiving hepatitis B immunoglobulin (HBIG) once a month during the third trimester of pregnancy, they were divided into either the HBIG-receiving group or the non-HBIG-receiving group. All infants received regular passive and active HBV immunization after birth. Infant serum HBV markers were determined 8-12 months after birth. Twenty infants born to HBsAg-positive mothers were infected with HBV and the failure rate of immune interruptions was 3.0%. The failure rate of immune interruptions in the HBeAg-positive group was 8.7%, which was significantly higher than that observed in HBeAg-negative group 0.2% (P<0.001). However, the HBV surface antibody (HBsAb) positive rates of the infants between the two groups were not statistically different (P=0.988). The overall failure rate of immune interruptions of infants born to the HBV DNA-positive group was 8.1%, and the infants infected with HBV were all born to the mothers whose serum HBV DNA levels were above 6 log10 copies/ml. There were no statistical differences in the incidence of perinatal HBV infection between mothers receiving HBIG and those not receiving HBIG (3.7% vs 2.7%, P=0.479). No statistical differences were seen in HBsAb positive rates versus vaccination of the infants between the two groups (84.4% vs 82.4%, P=0.519). Among HBeAg-positive pregnant women receiving HBIG, the failure rate of immune interruptions in their infants was 8.4%, compared with 8.9% in those who did not receive HBIG, with no statistical differences (P=0.892). Importantly, 10 out of 11 infants who were infected with HBV were already serum HBsAg-positive immediately after birth, suggesting intrauterine infection either via venous or cord blood. These results indicate that preventative vaccine immunization plus HBIG administration does not block intrauterine transmission of HBV. Approaches to decrease the serum HBV DNA load in pregnant women by antiviral treatment may efficiently block mother-to-infant transmission.

Decreased placental TLR3 is associated with hepatitis B virus vaccine responsiveness in infants born to HBsAg-positive mothers

Impaired trophoblast Toll-Like Receptor 3 signaling pathway involves in hepatitis B vaccine non- or hypo-response of infants born to HBsAg-positive mothers

Relationship between TLR3 expression in placenta and hepatitis B virus infection in pregnant women

Impaired CD8+ T Cells in Term Pregnancy Decidua with Chronic Hepatitis B Virus Infection

Effect of Prophylactic Antiviral Intervention on T Cell Immunity in Hepatitis B Virus-Infected Pregnant Women

No response to hepatitis B vaccine in infants born to HBsAg(+) mothers is associated to the transplacental transfer of HBsAg

Distribution of TLR3 in human placenta from normal and HBsAg-positive pregnant women

Risk Factors of HBsAg Positive Pregnant Women Placental Tissue Infection and Its Relationship with Toll Like Receptor 3

Potential Roles Of Placental Human Beta-Defensin-3 And Apolipoprotein B Mrna-Editing Enzyme Catalytic Polypeptide 3g In Prevention Of Intrauterine Transmission Of Hepatitis B Virus

DETECTION OF TLR3 EXPRESSION IN PLACENTA OF PREGNANT WOMEN WITH HBV INFECTION BY QRTPCR

Toll Like Receptor 3 Expression And Function On Peripheral Blood Mononuclear Cell In Pregnant Women With Hbv Infection

[Effects of neonatal stimulator of interferon genes innate immune signaling pathway of HBsAg-positive mothers on non/hypo-response to hepatitis B vaccine in infants]

Involvement of Viperin in Prevention of Intrauterine Transmission of Hepatitis B Virus

20 μg hepatitis B vaccination reduced the risk of low responsiveness in infants with HLA-II risk genotype of HBsAg positive mothers

Study of the relationship in pregnant women between hepatitis B markers and a placenta positive for hepatitis B surface antigen

The relationship of maternal hepatitis B e antigen and response to vaccination of infants born to women with chronic infection

Immune Response to Hepatitis B Vaccine in Children Born to HBsAg Positive Mothers: a Meta-Regression Analysis

Serological positive markers of hepatitis B virus in femoral venous blood or umbilical cord blood should not be evidence of in-utero infection among neonates

Study on dependablity between the intrauterine transmission of hepatitis B virus and expression of mitogen activator protien kinase in placenta of chronicity type B hepatitis pregnant women

The efficacy of immune interruptions on blocking mother-toinfant transmission of hepatitis B virus

The effects of increased dose of hepatitis B vaccine on mother-to-child transmission and immune response for infants born to mothers with chronic hepatitis B infection: a prospective, multicenter, large-sample cohort study